Canaccord raised the firm’s price target on Hims & Hers to $32 from $30 and keeps a Buy rating on the shares. The firm said Hims reported mixed Q1 results, with both revenue and adjusted EBITDA coming in modestly below expectations. Growth was pressured by a difficult y/y comp resulting from record weight loss net adds as well as shorter shipping cadences tied to the strategic pivot toward branded GLP-1s.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target raised to $28 from $24 at Citi
- Closing Bell Movers: Hims & Hers down 12% on earnings miss
- HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets
- Bullish flow in Hims and Hers Health with shares up 3.13%
- Notable companies reporting after market close